Atanib (Afatinib)
Therapeutic Group : Tyrosine Kinase Inhibitor (Oncology) Presentation: ATANIB 40 mg Tablet: Each film coated tablet contains Afatinib Dimaleate INN 59.12 mg equivalent to Afatinib 40 mg. Pharmacology: Mechanism of action: Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of […]